Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

Published:2014 Issue:3 Volume:20 Page:343-348
ISSN:1359-6535
Container-title:Antiviral Therapy
language:
Short-container-title:Antivir Ther

Author:

Akil Bisher, ,Blick Gary,Hagins Debbie P,Ramgopal Moti N,Richmond Gary J,Samuel Rafik M,Givens Naomi,Vavro Cindy,Song Ivy H,Wynne Brian,Ait-Khaled Mounir

Publisher

SAGE Publications

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics;Clinical Pharmacology & Therapeutics;2024-07-16

2. Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1;The Journal of Clinical Pharmacology;2024-07-16

3. Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure–response analysis in pediatrics;AIDS;2024-05-17

4. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis;The Lancet HIV;2023-11

5. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1;Infectious Diseases and Therapy;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP